- Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
- Innovative inhaler offers asthma and COPD patients a new therapeutic option
- Now available to patients in 14 countries, as global roll-out continues apace
Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.
AirFluSal, which was first approved in Denmark, has now been launched in a …